Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Gene Ther ; 23(10): 753-759, 2016 10.
Article in English | MEDLINE | ID: mdl-27416077

ABSTRACT

Immune responses against multiple epitopes are required for the prevention of hepatitis C virus (HCV) infection, and the progression to phase I trials of candidates may be guided by comparative immunogenicity studies in non-human primates. Four vectors, DNA, SFV, human serotype 5 adenovirus (HuAd5) and Modified Vaccinia Ankara (MVA) poxvirus, all expressing hepatitis C virus Core, E1, E2 and NS3, were combined in three prime-boost regimen, and their ability to elicit immune responses against HCV antigens in rhesus macaques was explored and compared. All combinations induced specific T-cell immune responses, including high IFN-γ production. The group immunized with the SFV+MVA regimen elicited higher E2-specific responses as compared with the two other modalities, while animals receiving HuAd5 injections elicited lower IL-4 responses as compared with those receiving MVA. The IFN-γ responses to NS3 were remarkably similar between groups. Only the adenovirus induced envelope-specific antibody responses, but these failed to show neutralizing activity. Therefore, the two novel regimens failed to induce superior responses as compared with already existing HCV vaccine candidates. Differences were found in response to envelope proteins, but the relevance of these remain uncertain given the surprisingly poor correlation with immunogenicity data in chimpanzees, underlining the difficulty to predict efficacy from immunology studies.


Subject(s)
B-Lymphocytes/immunology , Epitopes/genetics , Hepacivirus/immunology , T-Lymphocytes/immunology , Viral Hepatitis Vaccines/immunology , Adenoviridae/genetics , Animals , Cell Line , Cricetinae , Epitopes/immunology , Genetic Vectors/genetics , Immunogenicity, Vaccine , Interferon-gamma/blood , Interleukin-4/blood , Macaca mulatta , Male , Vaccinia virus/genetics , Viral Hepatitis Vaccines/genetics
2.
Free Radic Biol Med ; 45(12): 1729-37, 2008 Dec 15.
Article in English | MEDLINE | ID: mdl-18930811

ABSTRACT

Reactive oxygen species (ROS) and subsequent oxidative damage may contribute to the formation and persistence of multiple sclerosis (MS) lesions by acting on distinct pathological processes. ROS initiate lesion formation by inducing blood-brain barrier disruption, enhance leukocyte migration and myelin phagocytosis, and contribute to lesion persistence by mediating cellular damage to essential biological macromolecules of vulnerable CNS cells. Relatively little is known about which CNS cell types are affected by oxidative injury in MS lesions. Here, we show the presence of extensive oxidative damage to proteins, lipids, and nucleotides occurring in active demyelinating MS lesions, predominantly in reactive astrocytes and myelin-laden macrophages. Oxidative stress can be counteracted by endogenous antioxidant enzymes that confer protection against oxidative damage. Here, we show that antioxidant enzymes, including superoxide dismutase 1 and 2, catalase, and heme oxygenase 1, are markedly upregulated in active demyelinating MS lesions compared to normal-appearing white matter and white matter tissue from nonneurological control brains. Particularly, hypertrophic astrocytes and myelin-laden macrophages expressed an array of antioxidant enzymes. Enhanced antioxidant enzyme production in inflammatory MS lesions may reflect an adaptive defense mechanism to reduce ROS-induced cellular damage.


Subject(s)
Antioxidants/metabolism , Catalase/metabolism , Heme Oxygenase-1/metabolism , Multiple Sclerosis/enzymology , Multiple Sclerosis/pathology , Oxidative Stress , Superoxide Dismutase/metabolism , Adult , Aged , Aged, 80 and over , Astrocytes/enzymology , Brain/enzymology , Brain/pathology , Case-Control Studies , Female , Humans , Immunoenzyme Techniques , Macrophages/enzymology , Male , Middle Aged , Superoxide Dismutase-1
3.
J Virol ; 78(1): 187-96, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14671100

ABSTRACT

Prophylactic hepatitis C virus (HCV) vaccine trials with human volunteers are pending. There is an important need for immunological end points which correlate with vaccine efficacy and which do not involve invasive procedures, such as liver biopsies. By using a multicomponent DNA priming-protein boosting vaccine strategy, naïve chimpanzees were immunized against HCV structural proteins (core, E1, and E2) as well as a nonstructural (NS3) protein. Following immunization, exposure to the heterologous HCV 1b J4 subtype resulted in a peak of plasma viremia which was lower in both immunized animals. Compared to the naïve infection control and nine additional historical controls which became chronic, vaccinee 2 (Vac2) rapidly resolved the infection, while the other (Vac1) clearly controlled HCV infection. Immunization induced antibodies, peptide-specific gamma interferon (IFN-gamma), protein-specific lymphoproliferative responses, IFN-gamma, interleukin-2 (IL-2), and IL-4 T-helper responses in both vaccinees. However, the specificities were markedly different: Vac2 developed responses which were lower in magnitude than those of Vac1 but which were biased towards Th1-type cytokine responses for E1 and NS3. This proof-of-principle study in chimpanzees revealed that immunization with a combination of nonstructural and structural antigens elicited T-cell responses associated with an alteration of the course of infection. Our findings provide data to support the concept that the quality of the response to conserved epitopes and the specific nature of the peripheral T-helper immune response are likely pivotal factors influencing the control and clearance of HCV infection.


Subject(s)
Hepacivirus/immunology , Hepatitis C, Chronic/prevention & control , Th1 Cells/immunology , Th2 Cells/immunology , Viral Hepatitis Vaccines/immunology , Animals , Cytokines/biosynthesis , Hepacivirus/pathogenicity , Hepatitis C Antibodies/blood , Hepatitis C Antigens/immunology , Hepatitis C, Chronic/immunology , Humans , Immunization , Lymphocyte Activation/immunology , Pan troglodytes , Viral Core Proteins/immunology , Viral Hepatitis Vaccines/administration & dosage , Viral Nonstructural Proteins/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...